

Claudia Maletzki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6410115/publications.pdf>

Version: 2024-02-01

41
papers

774
citations

516710

16
h-index

580821

25
g-index

45
all docs

45
docs citations

45
times ranked

1368
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical Head and Neck Squamous Cell Carcinoma Models for Combined Targeted Therapy Approaches. <i>Cancers</i> , 2022, 14, 2484.	3.7	1
2	Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	5
3	CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors. <i>OncImmunology</i> , 2022, 11, .	4.6	8
4	Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastomaâ€”backbone or add-on in immune-oncology?. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 153-171.	5.9	23
5	Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models. <i>Cell Death Discovery</i> , 2021, 7, 54.	4.7	17
6	Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3405-3419.	4.2	5
7	The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cellsâ€”A Systematic Analysis. <i>Cancers</i> , 2021, 13, 2396.	3.7	6
8	Cyclin-Dependent Kinase Inhibitors in Hematological Malignanciesâ€”Current Understanding, (Pre-)Clinical Application and Promising Approaches. <i>Cancers</i> , 2021, 13, 2497.	3.7	12
9	Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5990.	4.1	12
10	Establishment and characterization of patient-derived head and neck cancer models from surgical specimens and endoscopic biopsies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 246.	8.6	8
11	NSG mice as hosts for oncological precision medicine. <i>Laboratory Investigation</i> , 2020, 100, 27-37.	3.7	26
12	High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation. <i>Modern Pathology</i> , 2020, 33, 1220-1231.	5.5	6
13	In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters. <i>Journal of Translational Medicine</i> , 2020, 18, 402.	4.4	13
14	<i>Streptococcus gallolyticus</i> abrogates anti-carcinogenic properties of tannic acid on low-passage colorectal carcinomas. <i>Scientific Reports</i> , 2020, 10, 4714.	3.3	17
15	Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib. <i>Frontiers in Immunology</i> , 2020, 11, 55.	4.8	25
16	Unraveling the Heterogeneous Mutational Signature of Spontaneously Developing Tumors in MLH1âˆ’/âˆ’ Mice. <i>Cancers</i> , 2019, 11, 1485.	3.7	7
17	Targeting Immune-Related Molecules in Cancer Therapy: A Comprehensive In Vitro Analysis on Patient-Derived Tumor Models. <i>BioMed Research International</i> , 2019, 2019, 1-12.	1.9	9
18	Suspected Hereditary Cancer Syndromes in Young Patients: Heterogeneous Clinical and Genetic Presentation of Colorectal Cancers. <i>Oncologist</i> , 2019, 24, 877-882.	3.7	1

#	ARTICLE	IF	CITATIONS
19	Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer. , 2019, 7, 8.		13
20	Cellular vaccination of MLH1 ^{+/+} mice – an immunotherapeutic proof of concept study. <i>Oncolimmunology</i> , 2018, 7, e1408748.	4.6	13
21	Arginine-Depleting Enzymes – An Increasingly Recognized Treatment Strategy for Therapy-Refractory Malignancies. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 854-870.	1.6	58
22	Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair deficiency and Lynch syndrome. <i>Molecular Carcinogenesis</i> , 2017, 56, 1753-1764.	2.7	13
23	Deciphering molecular mechanisms of arginine deiminase-based therapy – Comparative response analysis in paired human primary and recurrent glioblastomas. <i>Chemico-Biological Interactions</i> , 2017, 278, 179-188.	4.0	15
24	Colorectal carcinoma tumour budding and podia formation in the xenograft microenvironment. <i>PLoS ONE</i> , 2017, 12, e0186271.	2.5	14
25	Application of <i>in vivo</i> imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer. <i>Oncotarget</i> , 2017, 8, 69756-69767.	1.8	10
26	The mutational profile and infiltration pattern of murine MLH1 ^{-/-} tumors: concurrences, disparities and cell line establishment for functional analysis. <i>Oncotarget</i> , 2016, 7, 53583-53598.	1.8	12
27	Arginine deprivation by arginine deiminase of <i>Streptococcus pyogenes</i> controls primary glioblastoma growth <i>in vitro</i> and <i>in vivo</i> . <i>Cancer Biology and Therapy</i> , 2015, 16, 1047-1055.	3.4	52
28	Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype. <i>PLoS ONE</i> , 2015, 10, e0143194.	2.5	12
29	Establishment and characterization of cell lines from chromosomal instable colorectal cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 164.	3.3	27
30	Host defense peptides for treatment of colorectal carcinoma - a comparative <i>in vitro</i> and <i>in vivo</i> analysis. <i>Oncotarget</i> , 2014, 5, 4467-4479.	1.8	20
31	Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies. <i>European Journal of Cancer</i> , 2013, 49, 2587-2595.	2.8	28
32	Microsatellite instability in hematological malignancies. <i>Oncolimmunology</i> , 2013, 2, e25419.	4.6	4
33	Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-14.	3.3	26
34	S100 Proteins as Diagnostic and Prognostic Markers in Colorectal and Hepatocellular Carcinoma. <i>Hepatitis Monthly</i> , 2012, 122, e7240.	0.2	24
35	Ex-vivo Clonally Expanded B Lymphocytes Infiltrating Colorectal Carcinoma Are of Mature Immunophenotype and Produce Functional IgG. <i>PLoS ONE</i> , 2012, 7, e32639.	2.5	40
36	Establishment, Characterization and Chemosensitivity of Three Mismatch Repair Deficient Cell Lines from Sporadic and Inherited Colorectal Carcinomas. <i>PLoS ONE</i> , 2012, 7, e52485.	2.5	49

#	ARTICLE	IF	CITATIONS
37	Avitalized bacteria mediate tumor growth control via activation of innate immunity. Cellular Immunology, 2011, 269, 120-127.	3.0	17
38	An MSI Tumor Specific Frameshift Mutation in a Coding Microsatellite of MSH3 Encodes for HLA-A0201-Restricted CD8+ Cytotoxic T Cell Epitopes. PLoS ONE, 2011, 6, e26517.	2.5	25
39	Bacteriolytic therapy of experimental pancreatic carcinoma. World Journal of Gastroenterology, 2010, 16, 3546.	3.3	22
40	cis-Hydroxyproline-mediated pancreatic carcinoma growth inhibition in mice. International Journal of Colorectal Disease, 2010, 25, 921-929.	2.2	7
41	Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer, 2010, 10, 362.	2.6	72